Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects
Fig 5
CAM assay results for the three TKIs tested at their VEGFR2 IC50 value (vorolanib = 52nM, sunitinib = 43nM, and axitinib = 0.2nM).
(A) Representative images of gelatin sponge and surrounding vessels in ovo for negative control, positive control (anti-VEGF antibody, bevacizumab) and the three tested TKIs. Black arrows point at the white spot which is the location of the gelatin sponge. Scale bar is 1000 μm. (B) The number of macroscopic blood vessels perfusing the gelatin sponge for each TKI was determined (mean ± SEM). (C) The individual semi-quantitative scoring of vessel size for each TKI is shown (mean ± SEM). For panels B and C, statistical differences were made visible by the presence of stars: *0.01 < p ≤ 0.05; **0.001 < p ≤ 0.01; ***0.0001 ≤ p ≤ 0.001; ****p ≤ 0.0001. CAM, chorioallantoic membrane; IC50, half-maximal inhibitory concentration; SEM, standard error of the mean; TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.